Inovio Pharmaceuticals (INO)
(Delayed Data from NSDQ)
$6.48 USD
-0.21 (-3.14%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $6.47 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Inovio Pharmaceuticals, Inc. [INO]
Reports for Purchase
Showing records 221 - 240 ( 366 total )
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ApolloBio Agreement Amended With $23M Upfront Payment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Evidence of Synergy Between TERT and Checkpoint Inhibitors Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Efficacy Signals From Two Immuno-Oncology Therapies; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q Financial Results Reported; VGX-3100 Pivotal Program Forges Ahead; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A DNA Vaccine Fully Protects Non-Human Primates Against Lassa Fever Infection; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Phase 1b/2 Bladder Cancer Combo Regimen Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Data from First Zika Vaccine Human Trial Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Studies on dMAbs in Prostate Cancer and Bacterial Infection Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
INO-5150 Phase 1b Results; Multiple Data Readout Ahead; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q17 Results Reported; REVEAL Trials Recruiting; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Financing Completed; VGX-3100 Phase 3 Program Ongoing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Data of Plasmid DNA-encoded Monoclonal Antibody Against Influenza Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Inovio Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Hold Removed; VGX-3100 Phase 3 Trial Enrollment Begins; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.